Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In vitro tests show clinically tested drug overcomes resistance to potential new cancer therapy

03.04.2014

Results from laboratory experiments carried out by a team of molecular biologists at Saarland University have identified a strategy for overcoming resistance to a new therapeutic opportunity for prostate cancer patients and for potentially suppressing the migration of cancer cells.

The new therapeutic approach, which is currently being studied by numerous research groups, aims to destroy cancer cells by influencing cellular calcium distribution. However, the research team, supervised by Professor Richard Zimmermann and Dr Markus Greiner, found that in about half of the patients examined, a cellular mechanism was present that could impede the efficacy of the new therapy.

The molecular biologists discovered that this resistance was caused by an increased concentration of the protein Sec62 in the tumour cells. Results from their laboratory cell line experiments indicate that a pharmaceutically active agent previously used in the treatment of psychotic disorders can counteract the observed cellular resistance as well as supress cell migration. The research team has published its findings in the medical journal BMC Cancer.

Prostate cancer is the most common malignant tumour in men. A new therapeutic approach to combating the disease is currently the subject of international research. In recent years, US scientists have developed a number of analogues of thapsigargin that are capable of selectively killing tumour cells by emptying the calcium stores in these cells.

But recent research by scientists at Saarland University’s Faculty of Medicine in Homburg has demonstrated that in approximately half of the patients suffering from prostate cancer, the tumour cells can be expected to show a resistance to this new form of therapy.

‘The resistance mechanism is due to a higher concentration of the protein Sec62,’ explains Professor Richard Zimmermann. As a result of increased Sec62 levels the protein calmodulin can close the calcium leak channels more efficiently in the membrane of the important intracellular calcium store known as the endoplasmic reticulum. ‘This is why tumour cells with a higher concentration of Sec62 show greater resistance to treatment regimens based on thapsigargin analogues,’ says Zimmermann.

Working with tumour cell cultures in the laboratory, Zimmermann’s group at the Department of Medical Biochemistry and Molecular Biology has found a possible solution to the problem and their results have been published in the journal BMC Cancer. ‘Using tumour cell lines, we were able to show that a substance called trifluoperazine (TFP) was able to counteract the observed resistance. TFP has been used as an antipsychotic and was marketed in Germany under the brand Jatroneutral® where it was used in the treatment of psychotic disorders,’ explains Dr Markus Greiner, a member of Professor Zimmermann’s research team. ‘TFP binds directly to the protein calmodulin and thus impairs the calmodulin-mediated closure of the calcium channels,’ explains Greiner.

Sec62 has been shown to be an important tumour marker, i.e. a protein that occurs at enhanced concentrations in tumour cells, not only in prostate carcinomas, but also in thyroid and lung carcinomas. The Homburg researchers see a correlation between the presence of Sec62 protein and a more aggressive tumour and hence lower patient survival rates. The research team also measured increased Sec62 concentrations in tumours that had already metastasized.

‘Calcium is an important signalling molecule that regulates cell migration, which is itself an important contributor to tumour metastasis,’ says Markus Greiner. The calcium in the cells ensures that the cells can detect the direction in which they are migrating. If these tumour cells are treated with TFP, the calcium store will be emptied and the cells essentially lose their orientation. ‘This leads to an almost complete cessation of cellular migration,’ explains Greiner.

‘We propose a therapeutic approach based on TFP in combination with thapsigargin analogues. In future, this may be a therapeutic option for those many patients whose tumours have a high cellular concentration of Sec62, which might make them unsuitable for treatment with thapsigargin,’ says Greiner. The results obtained by the Homburg research team will now be evaluated in tumour model studies before any clinical trials can be proposed.

Original publication: Linxweiler M., Schorr S., Schäuble N., Jung M., Linxweiler J., Langer F., Schäfers H.-J., Cavaliè A., Zimmermann R., and Greiner M.: Targeting cell migration and Endoplasmic Reticulum stress response with calmodulin antagonists: Mimicking Sec62-depletion phenotypes by small molecule treatment, BMC Cancer, 2013, 13:574;
doi: 10.1186/1471-2407-13-574

Contact: Prof. Dr. Richard Zimmermann: +49 (0)6841 162-6511
E-mail: richard.zimmermann@uks.eu
Dr. Markus Greiner: +49 (0)6841 162-6515 E-mail: m.greiner@uks.eu

Press photographs are available at http://www.uni-saarland.de/pressefotos and can be used free of charge.

Claudia Ehrlich | Universität des Saarlandes

Further reports about: BMC Cancer TFP analogues calmodulin carcinomas concentration disorders mechanism resistance therapy tumour

More articles from Life Sciences:

nachricht Chains of nanogold – forged with atomic precision
23.09.2016 | Suomen Akatemia (Academy of Finland)

nachricht Self-assembled nanostructures hit their target
23.09.2016 | King Abdullah University of Science and Technology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Chains of nanogold – forged with atomic precision

23.09.2016 | Life Sciences

New leukemia treatment offers hope

23.09.2016 | Health and Medicine

Self-assembled nanostructures hit their target

23.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>